AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28551430 — intervention group
Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 28
Study 28552512 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 (0.5ml intramuscularly)
Number of subjects: 49
Study 28552987 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (anti-PD-L1 therapy)
Number of subjects: 29
Study 28554226 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-electrode switching system (MESS) radiofrequency ablation (RFA)
Number of subjects: 516
Study 28554585 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 79
Study 28554585 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline tricuspid annular plane systolic excursion (TAPSE)
Number of subjects: 79
Study 28554602 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine medication-assisted treatment (B-MAT)
Number of subjects: 476
Study 28554602 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitudes toward sharing buprenorphine
Number of subjects: 476
Study 28554602 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitudes toward selling buprenorphine
Number of subjects: 476
Study 28554656 — intervention group
Group type: EXPERIMENTAL
Intervention: Colon capsule endoscopy (CCE)
Number of subjects: 177
Study 28554917 — intervention group
Group type: EXPERIMENTAL
Intervention: Onco-TreC 2.0 remote monitoring system
Number of subjects: 80
Study 28554936 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal calgranulin C (S100A12) stool test
Number of subjects: 0
Study 28554936 — intervention group
Group type: COMPARATOR
Intervention: Faecal calprotectin (FC) stool test
Number of subjects: 0
Study 28554935 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-Test
Number of subjects: 350
Study 28555039 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acids (PUFA) supplementation, dosage and duration not specified
Number of subjects: 0
Study 28555039 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty acid desaturase activities, specific activities not specified
Number of subjects: 0
Study 28555339 — intervention group
Group type: EXPERIMENTAL
Intervention: iBGStar
Number of subjects: 100
Study 28555339 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring of blood glucose (SMBG) with Accu-Chek Nano
Number of subjects: 100
Study 28555519 — intervention group
Group type: EXPERIMENTAL
Intervention: E/C/F/TDF (switch group)
Number of subjects: 429
Study 28555519 — intervention group
Group type: COMPARATOR
Intervention: PI + RTV + TVD (no-switch group)
Number of subjects: 429
Study 28555533 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse Amplitude Tonometry (PAT) in patients with diabetic nephropathy
Number of subjects: 91
Study 28555533 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse Amplitude Tonometry (PAT) in patients with heart failure with preserved ejection fraction (HFpEF)
Number of subjects: 91
Study 28555533 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse Amplitude Tonometry (PAT) in patients with heart failure with reduced ejection fraction (HFrEF)
Number of subjects: 91
Study 28555533 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse Amplitude Tonometry (PAT) in patients with arterial hypertension
Number of subjects: 91
Study 28555565 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated neural activity and global brain connectivity in the intraparietal sulcus (IPS) during threat exposure.
Number of subjects: 0
Study 28558079 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum TpTe interval ≤ 50 ms
Number of subjects: 79
Study 28558079 — intervention group
Group type: COMPARATOR
Intervention: Child B
Number of subjects: 79
Study 28558079 — intervention group
Group type: COMPARATOR
Intervention: Child C
Number of subjects: 79
Study 28558079 — intervention group
Group type: COMPARATOR
Intervention: Child A
Number of subjects: 79
Study 28558663 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed fecal tests (at least two rounds)
Number of subjects: 41
Study 28558663 — intervention group
Group type: EXPERIMENTAL
Intervention: CRC screening blood test (potential option)
Number of subjects: 41
Study 28558737 — intervention group
Group type: EXPERIMENTAL
Intervention: Active case finding (ACF) strategies for TB, including clinic-based strategies (screening all patients regardless of visit purpose)
Number of subjects: 27
Study 28558737 — intervention group
Group type: EXPERIMENTAL
Intervention: Household outreach and incentive-based strategies
Number of subjects: 27
Study 28558737 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive case finding strategies
Number of subjects: 27
Study 28558737 — intervention group
Group type: EXPERIMENTAL
Intervention: Content analysis of interviews and focus groups
Number of subjects: 27
Study 28558800 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternity waiting homes (MWH) rated medium or high quality
Number of subjects: 17200
Study 28558800 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilities with MWH or space for pregnant waiting mothers
Number of subjects: 17200
Study 28558800 — intervention group
Group type: COMPARATOR
Intervention: Facilities without MWH or accommodations
Number of subjects: 17200
Study 28558812 — intervention group
Group type: EXPERIMENTAL
Intervention: Onsite antenatal syphilis screening intervention including onsite training, provision of supplies and medicines, quality control and supervision.
Number of subjects: 7
Study 28558812 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care test for syphilis.
Number of subjects: 7
Study 28559019 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib and cetuximab
Number of subjects: 13
Study 28559225 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based counseling combined with home-based HIV testing
Number of subjects: 400
Study 28559225 — intervention group
Group type: COMPARATOR
Intervention: Home-based HIV self-testing kits (control arm)
Number of subjects: 400
Study 28559225 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based HIV self-testing kits with video-based counseling (experimental arm)
Number of subjects: 400
Study 28559458 — intervention group
Group type: EXPERIMENTAL
Intervention: Team 2 (1 NP, 3 GPs)
Number of subjects: 9503
Study 28559458 — intervention group
Group type: EXPERIMENTAL
Intervention: Team 3 (2 NPs, 2 GPs)
Number of subjects: 9503
Study 28559458 — intervention group
Group type: COMPARATOR
Intervention: Team 1 (4 GPs)
Number of subjects: 9503
Study 28559537 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy followed by autologous stem cell transplantation (HCT-ASCT)
Number of subjects: 0
Study 28560656 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater social well-being (SWB) assessed with the social/family well-being subscale of the FACT-B
Number of subjects: 50
Study 28560656 — intervention group
Group type: COMPARATOR
Intervention: Emotional well-being, physical well-being, and functional well-being
Number of subjects: 50
Study 28562108 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPIs)
Number of subjects: 0
Study 28562108 — intervention group
Group type: COMPARATOR
Intervention: Histamine-2-receptor antagonists (H2RAs)
Number of subjects: 0
Study 28564715 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage endoscopic mucosal resection
Number of subjects: 0
Study 28564715 — intervention group
Group type: COMPARATOR
Intervention: Single-session approach
Number of subjects: 0
Study 28566263 — intervention group
Group type: COMPARATOR
Intervention: Control group (Treatment as usual with the endocrinologist and the nurse + Bodyguard2)
Number of subjects: 31
Study 28566263 — intervention group
Group type: EXPERIMENTAL
Intervention: PRECIOUS system (Bodyguard2 + PRECIOUS app)
Number of subjects: 31
Study 28566263 — intervention group
Group type: EXPERIMENTAL
Intervention: PRECIOUS system (Bodyguard2 + PRECIOUS app + Motivational Interviewing)
Number of subjects: 31
Study 28566290 — intervention group
Group type: EXPERIMENTAL
Intervention: Boston Scientific Lotus valve
Number of subjects: 537
Study 28566290 — intervention group
Group type: COMPARATOR
Intervention: Edwards Sapien 3 valve
Number of subjects: 537
Study 28566290 — intervention group
Group type: EXPERIMENTAL
Intervention: Boston Scientific Lotus valve and Edwards Sapien 3 valve
Number of subjects: 537
Study 28566292 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent right internal mammary artery device closure
Number of subjects: 50
Study 28566335 — intervention group
Group type: EXPERIMENTAL
Intervention: MenB-FHbp vaccine
Number of subjects: 17
Study 28566657 — intervention group
Group type: EXPERIMENTAL
Intervention: Leadless intracardiac transcatheter pacing system in Japanese patients
Number of subjects: 38
Study 28566948 — intervention group
Group type: EXPERIMENTAL
Intervention: NMDAR-Ab from ASD patient serum
Number of subjects: 1
Study 28566948 — intervention group
Group type: COMPARATOR
Intervention: NMDAR-Ab from seropositive healthy subject
Number of subjects: 1
Study 28567369 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral agents (DAAs) treatment
Number of subjects: 15
Study 28567369 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 15
Study 28567688 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-airway stimulation (UAS) device (Inspire Medical Systems)
Number of subjects: 26
Study 28568564 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorb BVS using PSP-technique
Number of subjects: 319
Study 28569047 — intervention group
Group type: EXPERIMENTAL
Intervention: Alglucerase/imiglucerase enzyme replacement therapy (ERT)
Number of subjects: 0
Study 28569141 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B Streptococcus (GBS) cases detected in selected hospitals
Number of subjects: 0
Study 28569141 — intervention group
Group type: EXPERIMENTAL
Intervention: GBS isolates
Number of subjects: 0
Study 28569141 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial susceptibility testing
Number of subjects: 0
Study 28569206 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-direct-acting-antiviral (DAA) regimen combining simeprevir (SMV), TMC647055/ritonavir (RTV), and JNJ-56914845
Number of subjects: 90
Study 28569206 — intervention group
Group type: COMPARATOR
Intervention: 2-DAA regimen SMV + TMC647055/RTV with or without ribavirin
Number of subjects: 90
Study 28569206 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-DAA regimen
Number of subjects: 90
Study 28569213 — intervention group
Group type: EXPERIMENTAL
Intervention: Mansoura-VV uterine compression sutures
Number of subjects: 108
Study 28569222 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive family history (PFH) of ankylosing spondylitis (AS)
Number of subjects: 1085
Study 28569222 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive family history (PFH) of acute anterior uveitis (AAU)
Number of subjects: 1085
Study 28569222 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive family history (PFH) of reactive arthritis (ReA)
Number of subjects: 1085
Study 28569222 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive family history (PFH) of inflammatory bowel disease (IBD)
Number of subjects: 1085
Study 28569222 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive family history (PFH) of psoriasis
Number of subjects: 1085
Study 28569603 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexicult™ SSI-Urinary Kit or ID Flexicult™ (POC urine culture tests)
Number of subjects: 341
Study 28569683 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative assessment through key stakeholder focus groups
Number of subjects: 0
Study 28569683 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative assessment involving height/weight measurement and dietary recalls
Number of subjects: 0
Study 28570698 — intervention group
Group type: EXPERIMENTAL
Intervention: CAA-related lobar ICH
Number of subjects: 77
Study 28570698 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep ICH
Number of subjects: 77
Study 28570698 — intervention group
Group type: COMPARATOR
Intervention: MCI-AD
Number of subjects: 77
Study 28570698 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 77
Study 28570742 — intervention group
Group type: EXPERIMENTAL
Intervention: Conformal radiation therapy (RT) individualized to a fixed risk of RT-induced lung toxicity (RILT) and adaptively escalated to the residual tumor defined on midtreatment FDG-PET up to a total dose of 86 Gy in 30 daily fractions, with concurrent weekly carboplatin plus paclitaxel.
Number of subjects: 42
Study 28570796 — intervention group
Group type: EXPERIMENTAL
Intervention: SRI-exposed group (women with a mood disorder taking SRI)
Number of subjects: 214
Study 28570796 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood Disorder group (women with depression or bipolar disorder not taking psychotropic medications)
Number of subjects: 214
Study 28570796 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (women not taking psychotropics and no major mood disorder)
Number of subjects: 214
Study 28570796 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm newborns
Number of subjects: 214
Study 28571635 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 179810
Study 28571635 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blockers in ST-segment elevation myocardial infarction
Number of subjects: 179810
Study 28571635 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blockers in non-ST-segment elevation myocardial infarction
Number of subjects: 179810
Study 28571635 — intervention group
Group type: COMPARATOR
Intervention: No β-blockers (Control)
Number of subjects: 179810
Study 28571639 — intervention group
Group type: EXPERIMENTAL
Intervention: Fontan procedure
Number of subjects: 373
Study 28571639 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise performance
Number of subjects: 373
Study 28571639 — intervention group
Group type: EXPERIMENTAL
Intervention: Ejection fraction
Number of subjects: 373
Study 28571639 — intervention group
Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide
Number of subjects: 373
Study 28571639 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Quality of Life Inventory physical summary score
Number of subjects: 373
Study 28572079 — intervention group
Group type: EXPERIMENTAL
Intervention: WelTel SMS text-message intervention
Number of subjects: 80
Study 28572163 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 514
Study 28574652 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg administered once daily
Number of subjects: 20
Study 28574663 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous adipose-derived regenerative cells (ADRC)
Number of subjects: 6
Study 28575201 — intervention group
Group type: EXPERIMENTAL
Intervention: PHIV women
Number of subjects: 2270
Study 28575201 — intervention group
Group type: EXPERIMENTAL
Intervention: PHIV women aged 23-30 years
Number of subjects: 2270
Study 28575201 — intervention group
Group type: COMPARATOR
Intervention: NPHIV women
Number of subjects: 2270
Study 28575278 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 million IU (MIU) of nebulized colistin methanesulfonate (CMS) administered every 8 hours as 30-minute nebulizations
Number of subjects: 12
Study 28575278 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 million IU (MIU) of nebulized colistin methanesulfonate (CMS)
Number of subjects: 12
Study 28575278 — intervention group
Group type: COMPARATOR
Intervention: 2 million IU (MIU) of nebulized colistin methanesulfonate (CMS)
Number of subjects: 12
Study 28575299 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment during childhood
Number of subjects: 9504
Study 28575323 — intervention group
Group type: EXPERIMENTAL
Intervention: darunavir/ritonavir (800/100 mg) once-daily regimen
Number of subjects: 7
Study 28575323 — intervention group
Group type: EXPERIMENTAL
Intervention: darunavir/cobicistat (800/150 mg) once-daily regimen
Number of subjects: 7
Study 28575467 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin 6 mg
Number of subjects: 52
Study 28575467 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 52
Study 28575467 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 28575476 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 0
Study 28575476 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive function
Number of subjects: 0
Study 28575476 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory Functioning Questionnaire (MFQ) measures
Number of subjects: 0
Study 28575523 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidaxomicin (16 mg/kg per day, up to 200 mg, twice daily for 10 days)
Number of subjects: 40
Study 28575536 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab treatment
Number of subjects: 85
Study 28576134 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher weight gain from 6 to 9 months, 9 to 12 months, and 12 to 15 months
Number of subjects: 0
Study 28576134 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher weight gain from 12 to 15 months
Number of subjects: 0
Study 28576134 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain in any period
Number of subjects: 0
Study 28576398 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD symptoms frequency and 12-month evolution
Number of subjects: 600
Study 28576398 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare resources utilization
Number of subjects: 600
Study 28576398 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory analysis
Number of subjects: 600
Study 28576754 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea treatment starting at approximately 20 mg/kg/day for 6 months, escalating to maximum tolerated dose (MTD) thereafter.
Number of subjects: 122
Study 28576754 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Doppler (TCD) screening for stroke risk.
Number of subjects: 122
Study 28576754 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea at maximum tolerated dose (MTD).
Number of subjects: 122
Study 28577353 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir 150 mg once daily plus Peginterferon α-2a/Ribavirin for 12 weeks followed by Peginterferon α-2a/Ribavirin for 12 or 36 weeks (response-guided therapy) or 36 weeks fixed (non-responders).
Number of subjects: 141
Study 28577957 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib (AZD9291) treatment
Number of subjects: 0
Study 28578302 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (administered per standard of care for 5 days)
Number of subjects: 143
Study 28578302 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (administered over 14 days)
Number of subjects: 143
Study 28578302 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacteroidetes/Ascomycota ratio
Number of subjects: 143
Study 28578302 — intervention group
Group type: COMPARATOR
Intervention: Cirrhotics (general population)
Number of subjects: 143
Study 28578535 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased daily water intake over 6 weeks
Number of subjects: 82
Study 28578624 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular revascularization in group 1 (younger than 80 years)
Number of subjects: 642
Study 28578624 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular revascularization in group 2 (80 years and older)
Number of subjects: 642
Study 28578624 — intervention group
Group type: COMPARATOR
Intervention: Comparison of freedom from MALE between groups
Number of subjects: 642
Study 28578624 — intervention group
Group type: COMPARATOR
Intervention: Comparison of limb salvage between groups
Number of subjects: 642
Study 28578664 — intervention group
Group type: EXPERIMENTAL
Intervention: CATT (5) genotype
Number of subjects: 256
Study 28578664 — intervention group
Group type: EXPERIMENTAL
Intervention: (5/5) genotype
Number of subjects: 256
Study 28578664 — intervention group
Group type: COMPARATOR
Intervention: Normal-coronary subjects
Number of subjects: 256
Study 28578664 — intervention group
Group type: COMPARATOR
Intervention: CAD class
Number of subjects: 256
Study 28578691 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild-intensity aerobic exercise
Number of subjects: 48
Study 28578691 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise
Number of subjects: 48
Study 28578691 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic exercise
Number of subjects: 48
Study 28578691 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 28578705 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-min sit-to-stand (1-min STS) test
Number of subjects: 409
Study 28578705 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip strength test
Number of subjects: 409
Study 28578708 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurally adjusted ventilatory assist (NAVA)
Number of subjects: 15
Study 28578708 — intervention group
Group type: COMPARATOR
Intervention: Pressure support ventilation (PSV)
Number of subjects: 15
Study 28578782 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthropometric measurements (body mass index, waist circumference, waist-to-hip ratio, waist-to-height ratio)
Number of subjects: 6268
Study 28579503 — intervention group
Group type: EXPERIMENTAL
Intervention: Good School Toolkit intervention
Number of subjects: 591
Study 28579503 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed control group
Number of subjects: 591
Study 28579536 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric fructose restriction for 9 days
Number of subjects: 41
Study 28579823 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release (IR) opioids (hydrocodone-acetaminophen and oxycodone-acetaminophen)
Number of subjects: 354
Study 28579823 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release (IR) opioids
Number of subjects: 354
Study 28580433 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccination
Number of subjects: 0
Study 28580456 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI; 6 sessions of MI + 8 weeks of NRT)
Number of subjects: 430
Study 28580456 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (Brief advice to quit + 8 weeks of NRT)
Number of subjects: 430
Study 28580793 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide plus Metformin (MET)
Number of subjects: 0
Study 28580917 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragment antigen-binding domains (Fabs) isolated from human monoclonal antibodies targeting NHBA
Number of subjects: 0